ASSISTANT PROFESSOR HUNG-YU SUN'S RESEARCH TEAM, NATIONAL CHENG KUNG UNIVERSITY (NCKU)
Area: Incubation
Booth No: N715A
Exhibitor Profile
MK53 is a novel peptide drug developed via an academia-industry platform and currently in preclinical development. Designed for type 2 diabetes and metabolic syndrome, it functions via a distinct mechanism from GLP-1 and SGLT2 drugs, enhancing insulin sensitivity and regulating glucose and lipid metabolism. Preclinical evaluation using a T2D mouse model shows initial improvements across metabolic parameters, supporting its translational potential.
Brands
Preclinical Evaluation of a Novel Peptide Targeting Metabolic Dysregulation in Type 2 Diabetes
Exhibitors you may be interested in
Highest Rated